{"paper_id":"f22dfebe-59ea-446e-aab1-f31eb3e547b4","body_text":"Abstract\nPurpose\nCurrently, 15% of gynaecological and 9% of haematological malignancies are diagnosed before the age of 40. The increased survival rates of cancer patients who are candidates for gonadotoxic treatments, the delay in childbearing to older ages, and the optimization of in vitro fertilisation techniques have all contributed to an increased interest in fertility preservation (FP) treatments. This study reviews the experience of the Fertility Preservation Programme (FPP) of a tertiary public hospital with a multidisciplinary approach.\nMethods\nThis retrospective study included all the available (FP) treatments, performed in patients of childbearing age between 2006 and 2022.\nResults\n1556 patients were referred to the FPP: 332 oocyte vitrification cycles, 115 ovarian cortex cryopreservation with 11 orthotopic autotransplantations, 175 gonadotropin-releasing hormone (GnRH) agonist treatments, 109 fertility-sparing treatments for gynaecological cancer, and 576 sperm cryopreservation were performed. Malignancy was the main indication for FP (the main indications being breast cancer in women and haematological malignancies in men), although non-oncological pathologies, such as endometriosis and autoimmune diseases, have increased in recent years. Currently, the most widely used FP technique is oocyte vitrification, the increase of which has been associated with a decrease in the use of cortex CP and GnRH agonists.\nConclusions\nThe increase in FP treatment reflects the implementation of reproductive counselling in oncology programmes. A multidisciplinary approach in a tertiary public hospital allows individualised FP treatment for each patient. In recent years, there has been a change in trend with the introduction of new indications for FP and a change in techniques due to their optimisation.\nSimilar content being viewed by others\nAbbreviations\n- FP:\n-\nFertility preservation\n- SLE:\n-\nSystemic lupus erythematosus\n- IVF:\n-\nIn vitro fertilisation\n- FPP:\n-\nFertility preservation programme\n- CP:\n-\nCryopreservation\n- GnRH:\n-\nGonadotrophin-releasing hormone\n- BOT:\n-\nBorderline ovarian tumours\n- SD:\n-\nStandard deviation\nReferences\nWorld Health Organization, International Agency for Research on Cancer (IARC), Global Cancer Observatory (GCO). https://gco.iarc.fr. Accessed 10 Oct 2022.\nSalama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol. 2019;30(11):1760–75. https://doi.org/10.1093/annonc/mdz284.\nCoward S, Clement F, Benchimol EI, Bernstein CN, Avina-Zubieta JA, Bitton A, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156(5):1345-1353.e4. https://doi.org/10.1053/j.gastro.2019.01.002.\nNusbaum JS, Mirza I, Shum J, Freilich RW, Cohen RE, Pillinger MH, et al. Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis. Mayo Clin Proc. 2020;95(2):384–94. https://doi.org/10.1016/j.mayocp.2019.09.012. (PMID:32029091).\nOktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO Clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001. https://doi.org/10.1200/JCO.2018.78.1914.\nEthics Committee of the American Society for Reproductive Medicine. Electronic address: ASRM@asrm.org. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril. 2018;110(3):380–6. https://doi.org/10.1016/j.fertnstert.2018.05.034.\nAnderson RA, Amant F, Braat D, D’Angelo A, de Chuva Sousa SM, Lopes SM, Demeestere I, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020. https://doi.org/10.1093/hropen/hoaa052.\nSelter J, Huang Y, Grossman Becht LC, Palmerola KL, Williams SZ, Forman E, et al. Use of fertility preservation services in female reproductive-aged cancer patients. Am J Obstet Gynecol. 2019;221(4):328.e1-328.e16. https://doi.org/10.1016/j.ajog.2019.05.009.\nSantaballa A, Márquez-Vega C, Rodriguez-Lescure Á, Rovirosa Á, Vázquez L, Zeberio-Etxetxipia I, et al. Multidisciplinary consensus on the criteria for fertility preservation in cancer patients. Clin Transl Oncol. 2022;24(2):227–43. https://doi.org/10.1007/s12094-021-02699-2.\nWorld Health Organization. WHO laboratory manual for the examination and processing of human semen. World Health Organization; 2021.\nVon Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod Biomed Online. 2015;31(5):605–12. https://doi.org/10.1016/j.rbmo.2015.07.013.\nEl Saghir NS, Khalil L, El Dick J, Atwani RW, Safi N, Charafeddine M, et al. Improved survival of young patients with breast cancer 40 years and younger at diagnosis. JCO Glob Oncol. 2023. https://doi.org/10.1200/GO.22.00354.\nBastings L, Baysal O, Beerendonk CC, Braat DD, Nelen WL. Referral for fertility preservation counselling in female cancer patients. Hum Reprod. 2014;29(10):2228–37. https://doi.org/10.1093/humrep/deu186.\nPractice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):37–43. https://doi.org/10.1016/j.fertnstert.2012.09.028.\nInstituto Nacional de Estadística. Statistics of the natural movement of the publication. 2021. https://www.ine.es. Accessed 2 Jan 2023.\nMartinez F, International Society for Fertility Preservation–ESHRE–ASRM Expert Working Group. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: indications, results and future perspectives. Fertil Steril. 2017;108(3):407-415.e11. https://doi.org/10.1016/j.fertnstert.2017.05.024.\nDiaz-Garcia C, Domingo J, Garcia-Velasco JA, Herraiz S, Mirabet V, Iniesta I, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478-485.e2. https://doi.org/10.1016/j.fertnstert.2017.11.018.\nCobo A, Giles J, Paolelli S, Pellicer A, Remohí J, García-Velasco JA. Oocyte vitrification for fertility preservation in women with endometriosis: an observational study. Fertil Steril. 2020;113(4):836–44. https://doi.org/10.1016/j.fertnstert.2019.11.017.\nCheca Vizcaíno MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online. 2012;24(6):606–10. https://doi.org/10.1016/j.rbmo.2012.02.020.\nde Melo GD, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, et al. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among patients with breast cancer. Oncologist. 2020;25(9):749–57. https://doi.org/10.1634/theoncologist.2019-0744.\nCavagna F, Pontes A, Cavagna M, Dzik A, Donadio NF, Portela R, et al. Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients. Curr Oncol. 2018;25:e527–32. https://doi.org/10.3747/co.25.3889.\nDonnez J, Dolmans MM. Fertility preservation in women. N Engl J Med. 2017;377(17):1657–65. https://doi.org/10.1056/NEJMra1614676.\nBeckmann MW, Dittrich R, Findeklee S, Lotz L. Surgical aspects of ovarian tissue removal and ovarian tissue transplantation for fertility preservation. Geburtshilfe Frauenheilkd. 2016;76(10):1057–64. https://doi.org/10.1055/s-0042-115017.\nDolmans MM, von Wolff M, Poirot C, Diaz-Garcia C, Cacciottola L, Boissel N, et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: a review of five leading European centers. Fertil Steril. 2021;115(5):1102–15. https://doi.org/10.1016/j.fertnstert.2021.03.008.\nAndersen CY, Bollerup AC, Kristensen SG. Defining quality assurance and quality control measures in connection with ovarian tissue cryopreservation and transplantation: a call to action. Hum Reprod. 2018;33(7):1201–4. https://doi.org/10.1093/humrep/dey105.\nLambertini M, Horicks F, Del Mastro L, Partridge AH, Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. Cancer Treat Rev. 2019;72:65–77. https://doi.org/10.1016/j.ctrv.2018.11.006.\nDemeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34(22):2568–74.\nLambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2020;31(12):1664–78. https://doi.org/10.1016/j.annonc.2020.09.006.\nCaponecchia L, Cimino G, Sacchetto R, Fiori C, Sebastianelli A, Salacone P, et al. Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia. 2016;48(3):333–40. https://doi.org/10.1111/and.12451.\nAnderson RA, Brewster DH, Wood R, Nowell S, Fischbacher C, Kelsey TW, et al. The impact of cancer on subsequent chance of pregnancy: a population-based analysis. Hum Reprod. 2018;33(7):1281–90. https://doi.org/10.1093/humrep/dey216.\nTaylan E, Oktay K. Fertility preservation in gynecologic cancers. Gynecol Oncol. 2019;155(3):522–9. https://doi.org/10.1016/j.ygyno.2019.09.012.\nvan der Plas RCJ, Bos AME, Jürgenliemk-Schulz IM, Gerestein CG, Zweemer RP. Fertility-sparing surgery and fertility preservation in cervical cancer: the desire for parenthood, reproductive and obstetric outcomes. Gynecol Oncol. 2021;163(3):538–44. https://doi.org/10.1016/j.ygyno.2021.09.003.\nDe Rocco S, Buca D, Oronzii L, Petrillo M, Fanfani F, Nappi L, et al. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;273:90–7. https://doi.org/10.1016/j.ejogrb.2022.04.019.\nPlett H, Harter P, Ataseven B, Heitz F, Prader S, Schneider S, et al. Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors. Gynecol Oncol. 2020;157(2):411–7. https://doi.org/10.1016/j.ygyno.2020.02.007.\nAuthor information\nAuthors and Affiliations\nCorresponding author\nEthics declarations\nConflict of interest\nAll authors declare that they have no conflict of interest related to this project.\nEthical approval (research involving human participants and/or animals)\nThis study involving human participants was reviewed and approved by the Ethical Committee of the Hospital Clinic of Barcelona.\nInformed consent\nAccording to legislation, participant informed consent was not necessary because of the retrospective nature of the study, the use of anonymized recorded clinical data, and the impossibility of identifying participants directly or through identifiers in the study results.\nAdditional information\nPublisher's Note\nSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.\nRights and permissions\nSpringer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.\nAbout this article\nCite this article\nBarral, Y., Borrás, A., Carrillo, P. et al. Current status of fertility preservation in a Spanish tertiary public hospital: multidisciplinary approach and experience in over 1500 patients. Clin Transl Oncol 26, 1129–1138 (2024). https://doi.org/10.1007/s12094-023-03330-2\nReceived:\nAccepted:\nPublished:\nVersion of record:\nIssue date:\nDOI: https://doi.org/10.1007/s12094-023-03330-2","source_license":"CC0","license_restricted":false}